Cargando…
Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study
BACKGROUND: In individuals suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis often extends over many years. Factors contributing to delayed diagnosis include health care professionals' limited knowledge of rare diseases and frequent (co-)occurrence o...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842899/ https://www.ncbi.nlm.nih.gov/pubmed/35164804 http://dx.doi.org/10.1186/s13023-022-02176-1 |
_version_ | 1784651141655560192 |
---|---|
author | Hebestreit, Helge Zeidler, Cornelia Schippers, Christopher de Zwaan, Martina Deckert, Jürgen Heuschmann, Peter Krauth, Christian Bullinger, Monika Berger, Alexandra Berneburg, Mark Brandstetter, Lilly Deibele, Anna Dieris-Hirche, Jan Graessner, Holm Gündel, Harald Herpertz, Stephan Heuft, Gereon Lapstich, Anne-Marie Lücke, Thomas Maisch, Tim Mundlos, Christine Petermann-Meyer, Andrea Müller, Susanne Ott, Stephan Pfister, Lisa Quitmann, Julia Romanos, Marcel Rutsch, Frank Schaubert, Kristina Schubert, Katharina Schulz, Jörg B. Schweiger, Susann Tüscher, Oliver Ungethüm, Kathrin Wagner, Thomas O. F. Haas, Kirsten |
author_facet | Hebestreit, Helge Zeidler, Cornelia Schippers, Christopher de Zwaan, Martina Deckert, Jürgen Heuschmann, Peter Krauth, Christian Bullinger, Monika Berger, Alexandra Berneburg, Mark Brandstetter, Lilly Deibele, Anna Dieris-Hirche, Jan Graessner, Holm Gündel, Harald Herpertz, Stephan Heuft, Gereon Lapstich, Anne-Marie Lücke, Thomas Maisch, Tim Mundlos, Christine Petermann-Meyer, Andrea Müller, Susanne Ott, Stephan Pfister, Lisa Quitmann, Julia Romanos, Marcel Rutsch, Frank Schaubert, Kristina Schubert, Katharina Schulz, Jörg B. Schweiger, Susann Tüscher, Oliver Ungethüm, Kathrin Wagner, Thomas O. F. Haas, Kirsten |
author_sort | Hebestreit, Helge |
collection | PubMed |
description | BACKGROUND: In individuals suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis often extends over many years. Factors contributing to delayed diagnosis include health care professionals' limited knowledge of rare diseases and frequent (co-)occurrence of mental disorders that may complicate and delay the diagnostic process. The ZSE-DUO study aims to assess the benefits of a combination of a physician focusing on somatic aspects with a mental health expert working side by side as a tandem in the diagnostic process. STUDY DESIGN: This multi-center, prospective controlled study has a two-phase cohort design. METHODS: Two cohorts of 682 patients each are sequentially recruited from 11 university-based German Centers for Rare Diseases (CRD): the standard care cohort (control, somatic expertise only) and the innovative care cohort (experimental, combined somatic and mental health expertise). Individuals aged 12 years and older presenting with symptoms and signs which are not explained by current diagnoses will be included. Data will be collected prior to the first visit to the CRD’s outpatient clinic (T0), at the first visit (T1) and 12 months thereafter (T2). OUTCOMES: Primary outcome is the percentage of patients with one or more confirmed diagnoses covering the symptomatic spectrum presented. Sample size is calculated to detect a 10 percent increase from 30% in standard care to 40% in the innovative dual expert cohort. Secondary outcomes are (a) time to diagnosis/diagnoses explaining the symptomatology; (b) proportion of patients successfully referred from CRD to standard care; (c) costs of diagnosis including incremental cost effectiveness ratios; (d) predictive value of screening instruments administered at T0 to identify patients with mental disorders; (e) patients’ quality of life and evaluation of care; and f) physicians’ satisfaction with the innovative care approach. CONCLUSIONS: This is the first multi-center study to investigate the effects of a mental health specialist working in tandem with a somatic expert physician in CRDs. If this innovative approach proves successful, it will be made available on a larger scale nationally and promoted internationally. In the best case, ZSE-DUO can significantly shorten the time to diagnosis for a suspected rare disease. Trial registration ClinicalTrials.gov; Identifier: NCT03563677; First posted: June 20, 2018, https://clinicaltrials.gov/ct2/show/NCT03563677. |
format | Online Article Text |
id | pubmed-8842899 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88428992022-02-16 Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study Hebestreit, Helge Zeidler, Cornelia Schippers, Christopher de Zwaan, Martina Deckert, Jürgen Heuschmann, Peter Krauth, Christian Bullinger, Monika Berger, Alexandra Berneburg, Mark Brandstetter, Lilly Deibele, Anna Dieris-Hirche, Jan Graessner, Holm Gündel, Harald Herpertz, Stephan Heuft, Gereon Lapstich, Anne-Marie Lücke, Thomas Maisch, Tim Mundlos, Christine Petermann-Meyer, Andrea Müller, Susanne Ott, Stephan Pfister, Lisa Quitmann, Julia Romanos, Marcel Rutsch, Frank Schaubert, Kristina Schubert, Katharina Schulz, Jörg B. Schweiger, Susann Tüscher, Oliver Ungethüm, Kathrin Wagner, Thomas O. F. Haas, Kirsten Orphanet J Rare Dis Research BACKGROUND: In individuals suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis often extends over many years. Factors contributing to delayed diagnosis include health care professionals' limited knowledge of rare diseases and frequent (co-)occurrence of mental disorders that may complicate and delay the diagnostic process. The ZSE-DUO study aims to assess the benefits of a combination of a physician focusing on somatic aspects with a mental health expert working side by side as a tandem in the diagnostic process. STUDY DESIGN: This multi-center, prospective controlled study has a two-phase cohort design. METHODS: Two cohorts of 682 patients each are sequentially recruited from 11 university-based German Centers for Rare Diseases (CRD): the standard care cohort (control, somatic expertise only) and the innovative care cohort (experimental, combined somatic and mental health expertise). Individuals aged 12 years and older presenting with symptoms and signs which are not explained by current diagnoses will be included. Data will be collected prior to the first visit to the CRD’s outpatient clinic (T0), at the first visit (T1) and 12 months thereafter (T2). OUTCOMES: Primary outcome is the percentage of patients with one or more confirmed diagnoses covering the symptomatic spectrum presented. Sample size is calculated to detect a 10 percent increase from 30% in standard care to 40% in the innovative dual expert cohort. Secondary outcomes are (a) time to diagnosis/diagnoses explaining the symptomatology; (b) proportion of patients successfully referred from CRD to standard care; (c) costs of diagnosis including incremental cost effectiveness ratios; (d) predictive value of screening instruments administered at T0 to identify patients with mental disorders; (e) patients’ quality of life and evaluation of care; and f) physicians’ satisfaction with the innovative care approach. CONCLUSIONS: This is the first multi-center study to investigate the effects of a mental health specialist working in tandem with a somatic expert physician in CRDs. If this innovative approach proves successful, it will be made available on a larger scale nationally and promoted internationally. In the best case, ZSE-DUO can significantly shorten the time to diagnosis for a suspected rare disease. Trial registration ClinicalTrials.gov; Identifier: NCT03563677; First posted: June 20, 2018, https://clinicaltrials.gov/ct2/show/NCT03563677. BioMed Central 2022-02-14 /pmc/articles/PMC8842899/ /pubmed/35164804 http://dx.doi.org/10.1186/s13023-022-02176-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Hebestreit, Helge Zeidler, Cornelia Schippers, Christopher de Zwaan, Martina Deckert, Jürgen Heuschmann, Peter Krauth, Christian Bullinger, Monika Berger, Alexandra Berneburg, Mark Brandstetter, Lilly Deibele, Anna Dieris-Hirche, Jan Graessner, Holm Gündel, Harald Herpertz, Stephan Heuft, Gereon Lapstich, Anne-Marie Lücke, Thomas Maisch, Tim Mundlos, Christine Petermann-Meyer, Andrea Müller, Susanne Ott, Stephan Pfister, Lisa Quitmann, Julia Romanos, Marcel Rutsch, Frank Schaubert, Kristina Schubert, Katharina Schulz, Jörg B. Schweiger, Susann Tüscher, Oliver Ungethüm, Kathrin Wagner, Thomas O. F. Haas, Kirsten Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study |
title | Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study |
title_full | Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study |
title_fullStr | Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study |
title_full_unstemmed | Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study |
title_short | Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study |
title_sort | dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (zse-duo): study protocol for a controlled multi-center cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842899/ https://www.ncbi.nlm.nih.gov/pubmed/35164804 http://dx.doi.org/10.1186/s13023-022-02176-1 |
work_keys_str_mv | AT hebestreithelge dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT zeidlercornelia dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT schipperschristopher dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT dezwaanmartina dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT deckertjurgen dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT heuschmannpeter dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT krauthchristian dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT bullingermonika dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT bergeralexandra dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT berneburgmark dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT brandstetterlilly dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT deibeleanna dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT dierishirchejan dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT graessnerholm dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT gundelharald dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT herpertzstephan dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT heuftgereon dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT lapstichannemarie dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT luckethomas dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT maischtim dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT mundloschristine dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT petermannmeyerandrea dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT mullersusanne dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT ottstephan dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT pfisterlisa dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT quitmannjulia dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT romanosmarcel dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT rutschfrank dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT schaubertkristina dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT schubertkatharina dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT schulzjorgb dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT schweigersusann dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT tuscheroliver dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT ungethumkathrin dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT wagnerthomasof dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT haaskirsten dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy AT dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy |